Encouraging results from phase 1/2 COVID-19 vaccine trials
- PMID: 32702300
- PMCID: PMC7832572
- DOI: 10.1016/S0140-6736(20)31611-1
Encouraging results from phase 1/2 COVID-19 vaccine trials
Erratum in
-
Department of Error.Lancet. 2020 Aug 15;396(10249):466. doi: 10.1016/S0140-6736(20)31722-0. Lancet. 2020. PMID: 32798486 Free PMC article. No abstract available.
Comment on
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702298 Free PMC article. Clinical Trial.
-
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702299 Free PMC article. Clinical Trial.
References
-
- Lurie N, Sharfstein JM, Goodman JL. The development of COVID-19 vaccines: safeguards needed. JAMA. 2020 https://doi.org.10.1001/jama.2020.12461 published online July 6. - PubMed
-
- Zhu F-C, Guan X-H, Li Y-H. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)31605-6. published online July 20. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources